abstract: A retrospective analysis of 33 @entity0 with @entity6 ( @entity6 ) seen in S  o Paulo, Brazil, from 1976 to 1985 at a @entity5 referral clinic revealed that @entity6 represents 2.5% of the total @entity5 cases seen. All cases were bilateral, 30% being @entity0 and 70% @entity0 . The ethnic distribution was the following: 60% white (with variable Indian or black extraction), 24% darkly pigmented, 9% Orientals (Sansei, third-generation Japanese) and 6% black. The frequency among Orientals was 7 times higher than what would be expected according to the relative frequency of Japanese in the Brazilian population. The age distribution at the onset of the disease was as follows: 12% less than 20 years of age, 60% between 20 and 40 years of age and 27% over 40 years of age. The disease was classified into 3 types with variable extraocular signs. @entity1 was present in 24% of the @entity0 , type II in 51% and @entity1 in 24% of the @entity0 . @entity3 was present in 40% of the cases and @entity4 was present in 9%. No correlation was found between sex, age at onset, race, type of extraocular involvement and number of extraocular manifestations in considering either visual status or visual prognosis. All @entity0 were treated with systemic @entity2 . Most of them also received cytotoxic immunosuppressive agents. In this uncontrolled clinical study cytotoxic drug-treated @entity0 seemed to have a better clinical course.

title: XXXX in Brazil.

answer: @entity6


abstract: Eighteen Holstein heifers were placed into groups of 3 according to projected calving date, prepartum BW, and prepartum condition score. Following parturition, animals within each group were assigned randomly to one of three diets and remained on the experiment for 45 d. Diets consisted of forage:concentrate ratios of 72:28, 53:47, or 73:27 (isocaloric to the 53:47 ratio by addition of 8% @entity3 oil). Diets were fed twice daily as total mixed rations. Blood, rumen fluid, and adipose tissue were sampled at -7, 5, 20, and 45 d of lactation. Performance means were, respectively: @entity5 intake (kg/d) 13.9, 14.9, and 12.4; milk (kg/d) 24.5, 25.8, and 18.6; milk fat (%) 3.77, 3.59, and 3.62; milk protein (%) 3.03, 2.99, and 3.11; body condition score (0 = thin, 5 = fat) 1.53, 1.87, and 1.99; and BW (kg) 514, 523, and 505. @entity0 fed @entity3 oil had higher ruminal isoacids than those fed the other diets and higher @entity1 than @entity0 on the 53:47 diet. Diets had no effect on blood metabolites or activity of adipose @entity2 -P dehydrogenase (EC 1.1.1.8). The @entity3 oil diet reduced short-chain @entity4 and increased long-chain @entity4 in milk. Feed intake and milk production were highest for @entity0 receiving the 53:47 diet. As expected, animals on the 72:28 diet did not consume adequate energy to maintain high production which concurrently resulted in lower body condition scores.

title: Effect of dietary energy source and concentration on performance of dairy XXXX during early lactation.

answer: @entity0


abstract: OBJECTIVE: To study the expression pattern of microRNAs and mRNAs related to @entity1 in @entity2 monocytes. DESIGN: A microRNA finding study on monocytes of @entity2 @entity0 and controls using array profiling was followed by a quantitative Real Time PCR (qPCR) study on monocytes of an Ecuadorian validation cohort testing the top over/under-expressed microRNAs. In addition, monocytes of the validation cohort were tested for 24 @entity1 -related mRNAs and 2 microRNAs previously found deregulated in (auto)-inflammatory monocytes. RESULTS: In the finding study, 142 significantly differentially expressed microRNAs were identified, 15 having the strongest power to discriminate @entity2 @entity0 from controls (sensitivity 66%, specificity 90%). However, differences in expression of these microRNAs between @entity0 and controls were small. On the basis of >1.4 or <0.6-fold change expression 5 microRNAs were selected for further validation. One microRNA (miR-34c-5p) was validated as significantly over-expressed in @entity2 monocytes. In addition, we found over expression of 3 mRNAs ( @entity6 , @entity7 and @entity10 ) in the validation cohort. These mRNAs are important for cell morphology, adhesion, shape change, and cell differentiation. Classical inflammatory genes (e.g. @entity5 ) were only over-expressed in monocytes of @entity0 with normal serum lipids. Remarkably, in @entity3 , there was a reduction in the expression of inflammatory genes (e.g. @entity9 , @entity8 and @entity4 ). CONCLUSIONS: The expression profile of microRNAs/mRNAs in monocytes of @entity2 @entity0 indicates an altered adhesion, differentiation, and shape change potential. Monocyte inflammatory activation was only found in @entity0 with normal serum lipids. Abnormal lipid values coincided with a reduced monocyte inflammatory state.

title: Type 2 Diabetes Monocyte MicroRNA and mRNA Expression: XXXX Associates with Increased Differentiation-Related Genes but Not Inflammatory Activation.

answer: @entity3


abstract: OBJECTIVE: @entity4 ( @entity4 ) has recently been shown to selectively target @entity0 cells with minimal effects on normal cells. We systematically assessed the effects of @entity4 in the treatment of @entity3 . METHODS: Three @entity1 cell lines, normal astrocytes, and endothelial cell lines were treated with @entity4 . The effects of @entity4 were then characterized for viability, @entity2 /apoptosis, and cell cycle effects. Statistical significance was determined with student's t-test. RESULTS: @entity4 treatment decreases viability of @entity1 cells in a dose dependent manner, with the ID50 between 90-120 seconds for all @entity1 cell lines. Treatment with @entity4 for more than 120 seconds resulted in viability less than 35% at 24-hours posttreatment, with a steady decline to less than 20% at 72-hours. In contrast, the effect of @entity4 on the viability of NHA and HUVEC was minimal, and importantly not significant at 90 to 120 seconds, with up to 85% of the cells remained viable at 72-hours post-treatment. @entity4 treatment produces both cytotoxic and apoptotic effects with some variability between cell lines. @entity4 treatment resulted in a G2/M-phase cell cycle pause in all three cell lines. CONCLUSIONS: This preliminary study determined a multi-focal effect of @entity4 on @entity1 cells in vitro, which was not observed in the @entity0 cell lines. The decreased viability depended on the treatment duration and cell line, but overall was explained by the induction of @entity2 , apoptosis, and G2/M pause. Future studies will aim at further characterization with more complex pre-clinical models.

title: Differential Effects of Cold Atmospheric Plasma in the Treatment of XXXX .

answer: @entity1


abstract: UNASSIGNED: Multivariate biomarkers that can predict the effectiveness of targeted therapy in individual @entity1 are highly desired. Previous biomarker discovery studies have largely focused on the identification of single biomarker signatures, aimed at maximizing prediction accuracy. Here, we present a different approach that identifies multiple biomarkers by simultaneously optimizing their predictive power, number of features, and proximity to the drug target in a protein-protein interaction network. To this end, we incorporated NSGA-II, a fast and elitist multi-objective optimization algorithm that is based on the principle of Pareto optimality, into the biomarker discovery workflow. The method was applied to quantitative phosphoproteome data of 19 @entity2 ( @entity2 ) cell lines from a previous biomarker study. The algorithm successfully identified a total of 77 candidate biomarker signatures predicting response to treatment with @entity3 . Through filtering and similarity clustering, this set was trimmed to four final biomarker signatures, which then were validated on an independent set of @entity0 cell lines. All four candidates reached the same good prediction accuracy (83%) as the originally published biomarker. Although the newly discovered signatures were diverse in their composition and in their size, the central protein of the originally published signature - @entity4 ( @entity4 ) - was also present in all four Pareto signatures, confirming its pivotal role in predicting @entity3 response in @entity2 cell lines. In summary, the method presented here allows for a robust and simultaneous identification of multiple multivariate biomarkers that are optimized for prediction performance, size, and relevance.

title: Pareto Optimization Identifies Diverse Set of Phosphorylation Signatures Predicting Response to Treatment with XXXX .

answer: @entity3


abstract: INTRODUCTION: @entity2 is an emerging zoonosis notified mainly in the Southeast of Brazil, especially due to its high level of lethality. OBJECTIVE: To analyze the epidemiological and spatial pattern of the disease in the municipality of Valinhos (106,793 inhabitants), S  o Paulo, Southeastern region of Brazil, in the period between 2001 and 2012. METHODS: All laboratory-confirmed cases with likely site of @entity3 in the city (n = 49) notified in the Brazilian Case Registry Database were studied. Sites were geocoded using the cartographic base of the city and Google Earth (geographic coordinates) with correction according to the Brazilian Geodetic System. We used the Kernel estimator to analyze the density of the cases on the map. Land cover and distance to basins of all cases were analyzed. Information about tick species and primary hosts were obtained from reports of the Superintendence of Control of @entity1 . RESULTS: Seasonality of the disease was observed with the highest incidence from June to November, and in 2005 and 2011. The most affected groups were @entity0 (79.6%) aged 20-49 years old (49%). Lethality was found to be 42.9%. Maps showed the progressive registration of cases in the urban area. Capybaras were reported as the main primary host, and Amblyomma cajennense was identified in probable sites of @entity3 during field investigation. The likely sites of @entity3 were mostly located near basins, dirty pastures, and bordering woods. CONCLUSIONS: The transmission pattern of @entity2 in Valinhos is similar to that in other cities in the region, where capybara is the main primary host and an amplifier of @entity4 . Over the years, a higher occurrence of cases has been identified in the urban area of the city.

title: Urbanization of XXXX in a municipality of the southeastern region: epidemiology and spatial distribution.

answer: @entity2


abstract: BACKGROUND: Tumor @entity2 factor (TNF)-related apoptosis-inducing ligand ( @entity4 ) induces apoptosis of various normal and @entity1 cells. Apoptosis plays an important role in the development of @entity3 ( @entity3 ). AIMS: The aim of this study was to determine whether the @entity5 polymorphism of the @entity4 gene is associated with the increased risk and severity of @entity3 in the Chinese Han population. METHODS: This study consisted of 312 @entity0 with @entity3 and 196 healthy controls. The grade of @entity3 was determined according to Schneiderman's classification for magnetic resonance imaging (MRI). RESULTS: The genotype frequency of the @entity5 polymorphism was in agreement with the Hardy-Weinberg equilibrium (p=0.278). @entity0 with @entity3 had significantly lower frequencies of CT and TT genotypes compared with normal controls (p<0.001). In addition, a lower frequency of the T allele was found in @entity0 with @entity3 than normal controls (p<0.001). Unconditional logistic regression analysis revealed that CT and TT genotypes were both significantly associated with a reduced risk of @entity3 compared with the CC genotype (p<0.001; odds ratio [OR] 0.327; 95% confidence interval [95% CI] 0.217-0.493 and p<0.001; OR 0.393; 95% CI 0.234-0.661, respectively). Furthermore, the T allele was significantly associated with a decreased risk of @entity3 compared with the C allele (p<0.001; OR 0.483; 95% CI 0.369-0.633). In addition, the CT and TT genotypes, as well as the T allele, were associated with lower degenerative grades of @entity3 compared with the CC genotype and the C allele, respectively (p=0.008 and p=0.001, respectively). CONCLUSION: The @entity5 polymorphism of @entity4 may be adversely associated with the risk and severity of @entity3 in the Chinese Han population.

title: Association of the Polymorphism of XXXX with the Risk and Severity of Lumbar Disc Degeneration in Chinese Han Population.

answer: @entity4


abstract: IMPORTANCE: The American Joint Committee on @entity1 (AJCC) has proposed the inclusion of pretreatment serum @entity3 ( @entity3 ) levels (C stage) into the conventional TNM staging system of @entity2 . The latter proposal has yet to be widely adopted because of the lack of long-term survival estimates of after C-stage incorporation into AJCC staging. OBJECTIVES: To evaluate whether long-term overall and cancer-specific survival is affected by inclusion of C stage into the standard AJCC TNM staging and to study the implications on survival estimates. DESIGN, SETTING, AND @entity0 : We performed a retrospective study of all @entity0 diagnosed as having histologically proven @entity2 from January 1, 2004, through December 31, 2005, from the National @entity1 Institute's Surveillance, Epidemiology, and End Results database. We stratified each AJCC stage as C0 (normal) or C1 (elevated) based on the pretreatment serum @entity3 level. Median follow-up was 71 months. MAIN OUTCOME AND MEASURES: Five-year estimates of overall and disease-specific survival and hazard ratios (HRs) for estimates of risk of overall and disease-specific mortality. RESULTS: A total of 16 619 @entity0 were evaluated, and of these, 8878 @entity0 had C0 disease and 7741 had C1 disease. C1 stage was independently associated with a 51% and 59% increased risk of overall (HR, 1.51; 95% CI, 1.44-1.59; P   <   .001) and disease-specific mortality (HR, 1.59; 95% CI, 1.49-1.69; P   <   . 001) at a median follow-up of 71 months. Analysis of survival of the AJCC stages subdivided as C0 or C1 revealed a significant worse prognosis of C1 AJCC stages compared with the respective C0 AJCC stages. The magnitude of change in survival was large enough to cause clustering of survival estimates of C1 vs C0 @entity1 across various AJCC stages. Analysis of @entity0 with @entity1 revealed that node-negative C1 disease was associated with prognosis similar or worse than node-positive C0 disease. CONCLUSIONS AND RELEVANCE: Inclusion of C stage into the AJCC TNM staging of @entity2 revealed significant differences dependent on C stage in terms of 5-year survival. C-stage inclusion resulted in substantial change in survival estimates, with C1 status portending a prognosis to certain stages similar to or worse than higher AJCC TNM stages with C0 status. We recommend routine pretreatment @entity3 testing as standard of care in @entity2 and use of C stage for multimodality treatment planning and risk stratification in prospective studies and randomized clinical trials.

title: Effect of Incorporation of Pretreatment Serum @entity3 Levels Into AJCC Staging for XXXX on 5-Year Survival.

answer: @entity2


abstract: IMPORTANCE: The American Joint Committee on @entity1 (AJCC) has proposed the inclusion of pretreatment serum @entity3 ( @entity3 ) levels (C stage) into the conventional TNM staging system of @entity2 . The latter proposal has yet to be widely adopted because of the lack of long-term survival estimates of after C-stage incorporation into AJCC staging. OBJECTIVES: To evaluate whether long-term overall and cancer-specific survival is affected by inclusion of C stage into the standard AJCC TNM staging and to study the implications on survival estimates. DESIGN, SETTING, AND @entity0 : We performed a retrospective study of all @entity0 diagnosed as having histologically proven @entity2 from January 1, 2004, through December 31, 2005, from the National @entity1 Institute's Surveillance, Epidemiology, and End Results database. We stratified each AJCC stage as C0 (normal) or C1 (elevated) based on the pretreatment serum @entity3 level. Median follow-up was 71 months. MAIN OUTCOME AND MEASURES: Five-year estimates of overall and disease-specific survival and hazard ratios (HRs) for estimates of risk of overall and disease-specific mortality. RESULTS: A total of 16 619 @entity0 were evaluated, and of these, 8878 @entity0 had C0 disease and 7741 had C1 disease. C1 stage was independently associated with a 51% and 59% increased risk of overall (HR, 1.51; 95% CI, 1.44-1.59; P   <   .001) and disease-specific mortality (HR, 1.59; 95% CI, 1.49-1.69; P   <   . 001) at a median follow-up of 71 months. Analysis of survival of the AJCC stages subdivided as C0 or C1 revealed a significant worse prognosis of C1 AJCC stages compared with the respective C0 AJCC stages. The magnitude of change in survival was large enough to cause clustering of survival estimates of C1 vs C0 @entity1 across various AJCC stages. Analysis of @entity0 with @entity1 revealed that node-negative C1 disease was associated with prognosis similar or worse than node-positive C0 disease. CONCLUSIONS AND RELEVANCE: Inclusion of C stage into the AJCC TNM staging of @entity2 revealed significant differences dependent on C stage in terms of 5-year survival. C-stage inclusion resulted in substantial change in survival estimates, with C1 status portending a prognosis to certain stages similar to or worse than higher AJCC TNM stages with C0 status. We recommend routine pretreatment @entity3 testing as standard of care in @entity2 and use of C stage for multimodality treatment planning and risk stratification in prospective studies and randomized clinical trials.

title: Effect of Incorporation of Pretreatment Serum XXXX Levels Into AJCC Staging for @entity2 on 5-Year Survival.

answer: @entity3


abstract: PURPOSE: To investigate the association of @entity2 ( @entity2 ) with @entity4 ( @entity4 ). DESIGN: Prospective, monocenter, cross-sectional case series. SUBJECTS: Sixteen @entity0 of 4 unrelated families with @entity4 caused by mutations in @entity3 . METHODS: All subjects underwent multimodal imaging including near-infrared (NIR) reflectance and fundus autofluorescence with a confocal scanning laser ophthalmoscope and spectral-domain optical coherence tomography (SD OCT). MAIN OUTCOME MEASURES: Prevalence, topographic distribution, and phenotype of @entity2 . RESULTS: Mean age of the investigated @entity0 was 56.8 years (range, 23-78 years). @entity2 were identified frequently in @entity4 @entity0 in the sixth decade of life (5 of 7 [71%]) and were absent in younger (n = 3) or older (n = 6) @entity0 . They were most abundant in the superior quadrant and spared the foveal region. @entity2 appeared as yellowish round to oval (dot subtype; n = 5) or confluent, wriggled (ribbon subtype; n = 3) lesions, sometimes forming irregular networks. @entity2 were hyporeflective on NIR reflectance and hypofluorescent on fundus autofluorescence imaging. They appeared as subretinal deposits on SD OCT imaging. Other lesions, such as peripheral pseudodrusen and soft drusen, were present less frequently. CONCLUSIONS: @entity2 are a frequent finding in @entity0 with @entity4 . Although @entity4 @entity0 with @entity2 are younger, distribution and phenotype of @entity2 are similar to those observed in @entity0 with age-related @entity1 . The association of @entity2 with @entity4 implicates a role of Bruch's membrane, the Bruch's membrane-retinal pigment epithelium interface, or both in the pathogenesis of @entity2 .

title: Reticular Pseudodrusen in XXXX .

answer: @entity4


abstract: @entity0 over the age of 10 years can lose their fusion ability. This acquired disruption of fusion gives rise to intractable @entity4 without @entity5 . An involuntary vertical bobbing movement of the non-fixing eye, present only with both eyes open, occurs at or near the angle of superimposition. This appears to be a unique and characteristic sign of acquired disruption of fusion and was present in all cases. Other causes of @entity4 are mentioned and differentiated. Acquired central fusion disruption usually results from serious @entity3 . Partial recovery may occur but is unlikely. Sensory deprivation of at least 3 1/2 years' duration due to @entity1 in one eye resulting from a traumatic @entity2 and sometimes subsequent uncorrected unilateral @entity6 caused loss of fusion in 15 @entity0 . The practical implications with regard to intraocular lenses and unilateral @entity6 is discussed. Less commonly, vascular, neoplastic and presumed inflammatory lesions in the mid-brain area cause central fusion disruption.

title: The loss of fusion in adults with intractable XXXX (central fusion disruption).

answer: @entity4


abstract: BACKGROUND: Reamed intramedullary nailing is the gold standard for management of femur @entity3 . Nailing within 24   h is proven to reduce complications from ongoing @entity4 , soft-tissue damage and @entity2 . However, when combined with @entity4 , femur @entity3 and intramedullary nailing are associated with immune-mediated damage to remote organs. We studied whether delaying @entity3 fixation until resuscitation was succeeding would lead to a significant @entity0 . METHODS: Twenty male @entity1 underwent closed femur @entity3 , @entity4 , resuscitation and either immediate nailing (group: ImmFix, n = 9), delayed nailing (group: DelFix, n = 8) or just splinting (group: NoFix, n = 3). @entity4 shock was maintained for 60   min. Resuscitation was with shed blood and Hartmann's solution. Animals were euthanized 8   h after fixation; the lungs and small bowel were scored histologically by two pathologists. RESULTS: Groups did not differ in weight, @entity4 volume or magnitude of shock. At 8   h, there was no difference in end-organ damage between ImmFix and DelFix groups (11.3    1.6 and 13.2    1.6 versus 8.1    1.3 and 12.9    1.1, P = 0.26 between groups). However, the NoFix group had significantly greater end-organ damage when compared with the fixation at any time groups (17.3    2.7 and 17.0    3.3 versus 9.8    1.1 and 13.1    1, P = 0.01 between groups). CONCLUSION: In this laboratory model, we have demonstrated that timely femur @entity3 fixation outweighs the potential harmful effects of surgery performed during @entity4 with simultaneous resuscitation. We have failed to demonstrate a difference between immediate and delayed fixation during resuscitation.

title: Influence of the timing of internal fixation of femur XXXX during shock resuscitation on remote organ damage.

answer: @entity3


abstract: BACKGROUND: @entity2 is a rare disease. Conflicting results on prognostic factors and extent of surgical resection for @entity0 with @entity2 have been made based on small sample sizes. A large, robust dataset is needed to help address some of the controversies. METHODS: A retrospective review of @entity0 with @entity2 in the National Cancer Data Base from 1985 to 2006 was performed. Characteristics of the cohort and type of treatment were evaluated. Prognostic factors were assessed with Cox proportional hazards regression models and 5- and 10-year OS rates were determined. RESULTS: There were 733 evaluable @entity0 with a mean age of 56.1      15.3  years (median 57, range 15-89) and mean @entity1 size of 29.6      18.4  mm (median 25.0  mm, range 10.0-150.0). @entity1 size, age at diagnosis, male sex, positive nodal status, and complete @entity1 resection had hazard ratios for death of 1.02 (1.01-1.02, p  <  0.0001), 1.06 (1.05-1.07, p  <  0.0001), 1.67 (1.24-2.25, p  =  0.0008), 1.25 (0.57-2.76, p  =  0.6), and 0.42 (0.22-0.81, p  =  0.01), respectively, on multivariable analysis. @entity0 who had removal of the @entity2 with concomitant resection of adjacent organs had HR for death of 0.70 (0.35-1.41, p  =  0.3). The 5- and 10-year OS rates were 82.3 and 66  % respectively. CONCLUSIONS: @entity0 age, @entity1 size, and sex have modest effects on survival in @entity0 with @entity2 . A staging system with prognostic value for @entity2 should include at least these pertinent prognostic factors.

title: XXXX : An Update on Treatment Outcomes and Prognostic Factors from the National Cancer Data Base (NCDB).

answer: @entity2


abstract: BACKGROUND: Accurate and early diagnosis of @entity2 ( @entity2 ) is a prerequisite for proper treatment and restricting disease propagation in @entity4 foci. An @entity5 antigen-based immunochromatographic test is now recommended for its diagnostic accuracy and operational feasibility at point of care. In @entity4 regions of Bangladesh, @entity5 or rKE16 antigen-based Rapid Diagnostic Tests (RDTs) are routinely performed on whole blood for diagnosis of @entity2 . However, manufacturer's instructions require use of serum. Therefore, we wanted to assess whether the diagnostic accuracy of these RDTs is as good on whole blood as on serum. METHODS: We evaluated and compared the sensitivity and specificity of five different commercially available RDTs on whole blood and on serum. We enrolled 30 @entity2 @entity0 , 35 @entity4 healthy controls and 30 @entity3 ( @entity3 ) @entity0 in our study from Mymensingh, a hyper- @entity4 region in Bangladesh. RESULTS: The sensitivity of all RDTs ranged between 96.67 % (95%CI: 82.72-99.44 %) and 100 % (95%CI: 96.34-100 %). The specificity ranged between 93.85 % (95%CI: 84.97-98.26 %) and 98.46 % (95%CI: 91.69-99.74 %), except for the Onsite leishmania Ab (Rev B) kit which showed markedly lower specificity (31.25-58.46 %). There was no significant difference in sensitivity and specificity between blood and serum. The Cohen kappa index (k >0.97) indicated excellent agreement. CONCLUSIONS: We conclude from the study that the use of blood for @entity1 in lieu of serum is appropriate for diagnosis of @entity2 in peripheral @entity4 regions provided the manufacturer recommendations are followed and the @entity1 is of good quality.

title: A comparative evaluation of the performance of commercially available rapid immunochromatographic tests for the diagnosis of XXXX in Bangladesh.

answer: @entity2


abstract: Prosthetic posterior chamber intraocular lenses can abrade the @entity2 pigmented epithelium, resulting in pigment dispersion, callus formation, and @entity2 adhesions. To evaluate @entity2 abrasion from intraocular lens materials, we developed an in vitro test and studied three materials: @entity3 ( @entity3 ), @entity1 , and @entity3 surface-modified by covalent binding of a hydrophilic polymer (surface-modified @entity3 ). Each lens was rubbed 1,000 times on the posterior @entity2 of pigmented @entity0 using a total force of 0.5 gram. Scanning electron micrographs of the abraded irides were scored using a subjective, nonparametric numerical scale. @entity3 lenses removed @entity2 epithelium completely, exposing underlying connective tissue. @entity1 lenses damaged an area longer and narrower than the @entity3 lens and also exposed connective tissue. Surface-modified @entity3 lenses caused only slight surface damage, including flattening or breaking of protruding suspensory ligaments. The test conditions used cannot precisely mimic prolonged lens implantation in living subjects. Nevertheless, the results indicate that @entity2 -lens interaction may be reduced in vivo by using a surface-modified @entity3 lens. This hypothesis should be further verified by animal implantation studies.

title: Intraocular lens material evaluation by XXXX abrasion in vitro: a scanning electron microscope study.

answer: @entity2


abstract: UNASSIGNED: @entity4 ( @entity4 ) is now the most common cause of chronic @entity3 among @entity0 and adolescents in the developed world. @entity6 , as a @entity5 donor, recently has been demonstrated to exert its hepatoprotective effects through rectifying the genomic DNA hypomethylation state. However, whether betaine supplementation affects @entity8 (m(6)A) mRNA methylation in @entity4 is still unknown. We conducted the current study to investigate the effects of betaine supplementation during adolescence on high-fat diet-induced pathological changes in liver of @entity1 , and we further identified the effects of betaine supplementation on expression of the fat mass and @entity2 -associated gene ( @entity9 ) and hepatic m(6)A mRNA methylation. Our results showed that betaine supplementation across adolescence significantly alleviated high-fat-induced @entity3 and morphology as well as ectopic fat accumulation. Surprisingly, no significant effects on serum TG and NEFA level, as well as fat mass, were observed in @entity1 supplemented with betaine. We also found that high-fat diet upregulated @entity10 and FAS gene expression and downregulated @entity7 and @entity11 gene expression. However, these alterations were rectified by betaine supplementation. Moreover, an m(6)A hypomethylation state and increased @entity9 expression were detected in @entity1 fed with high-fat diet, while betaine supplementation prevented these changes. Our results suggested that betaine supplementation during adolescence could protect @entity1 from high-fat-induced @entity4 by decreasing de novo lipogenesis and increasing lipolysis. Furthermore, a novel @entity9 -dependent function of m(6)A may involve in the hepatoprotective effects of betaine.

title: XXXX -dependent function of @entity8 is involved in the hepatoprotective effects of betaine on adolescent @entity1 .

answer: @entity9


abstract: UNASSIGNED: @entity4 ( @entity4 ) is now the most common cause of chronic @entity3 among @entity0 and adolescents in the developed world. @entity6 , as a @entity5 donor, recently has been demonstrated to exert its hepatoprotective effects through rectifying the genomic DNA hypomethylation state. However, whether betaine supplementation affects @entity8 (m(6)A) mRNA methylation in @entity4 is still unknown. We conducted the current study to investigate the effects of betaine supplementation during adolescence on high-fat diet-induced pathological changes in liver of @entity1 , and we further identified the effects of betaine supplementation on expression of the fat mass and @entity2 -associated gene ( @entity9 ) and hepatic m(6)A mRNA methylation. Our results showed that betaine supplementation across adolescence significantly alleviated high-fat-induced @entity3 and morphology as well as ectopic fat accumulation. Surprisingly, no significant effects on serum TG and NEFA level, as well as fat mass, were observed in @entity1 supplemented with betaine. We also found that high-fat diet upregulated @entity10 and FAS gene expression and downregulated @entity7 and @entity11 gene expression. However, these alterations were rectified by betaine supplementation. Moreover, an m(6)A hypomethylation state and increased @entity9 expression were detected in @entity1 fed with high-fat diet, while betaine supplementation prevented these changes. Our results suggested that betaine supplementation during adolescence could protect @entity1 from high-fat-induced @entity4 by decreasing de novo lipogenesis and increasing lipolysis. Furthermore, a novel @entity9 -dependent function of m(6)A may involve in the hepatoprotective effects of betaine.

title: @entity9 -dependent function of XXXX is involved in the hepatoprotective effects of betaine on adolescent @entity1 .

answer: @entity8


abstract: UNASSIGNED: @entity4 ( @entity4 ) is now the most common cause of chronic @entity3 among @entity0 and adolescents in the developed world. @entity6 , as a @entity5 donor, recently has been demonstrated to exert its hepatoprotective effects through rectifying the genomic DNA hypomethylation state. However, whether betaine supplementation affects @entity8 (m(6)A) mRNA methylation in @entity4 is still unknown. We conducted the current study to investigate the effects of betaine supplementation during adolescence on high-fat diet-induced pathological changes in liver of @entity1 , and we further identified the effects of betaine supplementation on expression of the fat mass and @entity2 -associated gene ( @entity9 ) and hepatic m(6)A mRNA methylation. Our results showed that betaine supplementation across adolescence significantly alleviated high-fat-induced @entity3 and morphology as well as ectopic fat accumulation. Surprisingly, no significant effects on serum TG and NEFA level, as well as fat mass, were observed in @entity1 supplemented with betaine. We also found that high-fat diet upregulated @entity10 and FAS gene expression and downregulated @entity7 and @entity11 gene expression. However, these alterations were rectified by betaine supplementation. Moreover, an m(6)A hypomethylation state and increased @entity9 expression were detected in @entity1 fed with high-fat diet, while betaine supplementation prevented these changes. Our results suggested that betaine supplementation during adolescence could protect @entity1 from high-fat-induced @entity4 by decreasing de novo lipogenesis and increasing lipolysis. Furthermore, a novel @entity9 -dependent function of m(6)A may involve in the hepatoprotective effects of betaine.

title: @entity9 -dependent function of @entity8 is involved in the hepatoprotective effects of betaine on adolescent XXXX .

answer: @entity1


abstract: Photostress recovery time was measured in 30 eyes from 15 @entity0 with @entity5 , and 30 eyes from 15 individuals of a similar age group with no @entity1 . The average recovery time in @entity0 with @entity3 was 70.47 (SD 35.39) seconds. The average recovery time in the control population was 41.97 (SD 17.34) seconds. This difference was statistically significant (p less than 0.001). There was a small positive correlation between age and recovery time in the control population, whereas there was no correlation between age and recovery time in the @entity3 group. There was no correlation between visual acuity and recovery time for either group. There was also no correlation between intraocular pressure and recovery time for the @entity3 group. It was not possible to control for @entity2 in this study. However, it has been previously demonstrated that pharmacological meiosis will not delay photostress recovery time in normal subjects. This is the first report of photostress recovery testing in @entity0 with @entity5 . The results are discussed in terms of the pathophysiology of @entity3 and previous photostress studies in @entity0 with @entity4 .

title: Photostress recovery in XXXX .

answer: @entity5


abstract: AIM: The objective of this study was to examine perinatal and neonatal properties of preterm @entity0 with a corrected age of 24-36 months who were born as a result of spontaneous and in vitro fertilization @entity3 , to interrogate somatic growth properties of these @entity0 and evaluate the factors which had an impact by comparing groups. MATERIAL AND METHODS: A total of 125 @entity0 with a birth weight below 2 500 g and a gestational age below the 37(th) gestational week 60 of whom were born as a result of in vitro fertilization @entity3 and 65 of whom were born as a result of spontaneous @entity3 were included in the study. Maternal age and morbidity, early rupture of membranes, birth weigth, gestational week, gender, APGAR score, hospitalization reasons in the neonatal period, requirement for intensive care, frequency of @entity2 , outpatient follow-up status, rehospitalization and socioeconomic levels were interrogated in the @entity0 . Detailed physical examination and current height, weight and head circumference measurements were performed and the findings were placed in the growth curves of Neyzi et al. Ethics committee approval was received for this study from the ethics committee of @entity4  rk  y Gynecology Obstetrics and Pediatrics Education and Research Hospital (12.10.2010; no:305). RESULTS: The rate of cesarean section, mean maternal age, the rate of @entity1 in the mother and the rate of maternal disease which occured during pregnancy were significantly higher in the in vitro fertilization group (p<0.05). While no difference was found in mean gestational age, birth weight, rate of hospitalization, time of hospitalization, frequency of follow-up in the intensive care unit, rates of @entity2 and rehospitalization, APGAR score in the 5(th) minute was significantly higher in the in vitro fertilization group. The socioeconomical score was not different between the groups, but the in vitro fertilization group presented more regularly for outpatient follow-up visits. Height, head circumference measurements and mean current weight were found to be significantly higher in the in vitro fertilization group (p<0.05). CONCLUSION: The fact that there was no difference in the rate of hospitalization, time of hospitalization, frequency of follow-up in the intensive care unit, rates of @entity2 and rehospitalization was attributed to the fact that the study and control groups were composed of only @entity3 and preterms.

title: Perinatal and somatic growth properties of preterm babies born from spontaneous and in vitro fertilization XXXX .

answer: @entity3


abstract: UNASSIGNED: Introduction. @entity1 ( @entity1 ) implies risk of suicide. The age at onset (AAO) of @entity1 carries prognostic significance. @entity3 may precede the onset of @entity1 and @entity4 is the most common illicit drug used. The main goal of this study is to review the association of @entity4 use as a risk factor for early onset of @entity1 and for suicide attempts. Materials and Methods. PubMed database was searched for articles using key words " @entity1 ," "suicide attempts," " @entity4 ," " @entity4 ," "early age at onset," and "early onset." Results. The following percentages in @entity1 @entity0 were found: suicide attempts 3.6-42%; suicide attempts and substance use 5-60%; suicide attempts and @entity4 use 15-42%. An early AAO was associated with @entity4 misuse. The mean age of the first @entity1 in individuals with and without @entity1 and @entity4 ( @entity4 ) was 19.5 and 25.1 years, respectively. The first @entity2 was at 18.5 and 24.4 years, respectively. Individuals misusing @entity4 showed increased risk of suicide. Discussion. Cannabis use is associated with increased risk of suicide attempts and with early AAO. However, the effect of @entity4 at the AAO and suicide attempts is not clear.

title: The Use of Cannabis as a Predictor of Early Onset of XXXX and Suicide Attempts.

answer: @entity1


abstract: BACKGROUND: @entity4 is a rare @entity1 seen in 2.15 @entity0 out of every 100,000 live births, with the most severe variant, @entity6 ( @entity6 ), only occurring in 1 in 200,000. @entity2 ( @entity2 ) describes a spectrum of disease ranging from mild hip instability to @entity5 . Underlying @entity3 , such as @entity8 and @entity7 , are often associated with the most severe variant of @entity2 , teratologic @entity2 . The varying degrees of severity in @entity2 have been encountered in classic @entity4 (CBE) @entity0 , but the exact incidence is unknown. We sought to determine the incidence of @entity2 in CBE and @entity6 @entity0 . METHODS: We performed a retrospective review of all @entity0 with CBE or @entity6 presenting to a single pediatric center between 1994 and 2014. Each chart was reviewed for correct diagnosis of CBE or @entity6 , @entity0 age and demographics, associated medical conditions, pertinent surgeries performed, and the age at operation. @entity0 imaging was reviewed to determine whether bilateral hip imaging was available. RESULTS: In a 20-year retrospective review, we identified 66 @entity0 who were diagnosed with either CBE or @entity6 and had available hip imaging (38 males and 28 females). Of these, 11 @entity0 were found to have radiographic evidence of @entity2 , for an incidence of 16.7% (11/66). Five of these @entity0 had @entity6 , whereas 6 presented with CBE. The first radiographic evidence of @entity2 was noted at a mean age of 5.75 years (range, birth to 22 y). CONCLUSIONS: We advocate the use of routine hip screening ultrasound in all @entity0 born with either CBE or @entity6 . Early identification of @entity2 in these @entity0 may allow additional treatment options to coincide with frequently used osteotomy and orthopaedic interventions. LEVEL OF EVIDENCE: Level III-retrospective study.

title: Incidence of XXXX Associated With @entity4 .

answer: @entity2


abstract: BACKGROUND: @entity4 is a rare @entity1 seen in 2.15 @entity0 out of every 100,000 live births, with the most severe variant, @entity6 ( @entity6 ), only occurring in 1 in 200,000. @entity2 ( @entity2 ) describes a spectrum of disease ranging from mild hip instability to @entity5 . Underlying @entity3 , such as @entity8 and @entity7 , are often associated with the most severe variant of @entity2 , teratologic @entity2 . The varying degrees of severity in @entity2 have been encountered in classic @entity4 (CBE) @entity0 , but the exact incidence is unknown. We sought to determine the incidence of @entity2 in CBE and @entity6 @entity0 . METHODS: We performed a retrospective review of all @entity0 with CBE or @entity6 presenting to a single pediatric center between 1994 and 2014. Each chart was reviewed for correct diagnosis of CBE or @entity6 , @entity0 age and demographics, associated medical conditions, pertinent surgeries performed, and the age at operation. @entity0 imaging was reviewed to determine whether bilateral hip imaging was available. RESULTS: In a 20-year retrospective review, we identified 66 @entity0 who were diagnosed with either CBE or @entity6 and had available hip imaging (38 males and 28 females). Of these, 11 @entity0 were found to have radiographic evidence of @entity2 , for an incidence of 16.7% (11/66). Five of these @entity0 had @entity6 , whereas 6 presented with CBE. The first radiographic evidence of @entity2 was noted at a mean age of 5.75 years (range, birth to 22 y). CONCLUSIONS: We advocate the use of routine hip screening ultrasound in all @entity0 born with either CBE or @entity6 . Early identification of @entity2 in these @entity0 may allow additional treatment options to coincide with frequently used osteotomy and orthopaedic interventions. LEVEL OF EVIDENCE: Level III-retrospective study.

title: Incidence of @entity2 Associated With XXXX .

answer: @entity4


abstract: BACKGROUND: Surgical treatment is recommended for @entity0 with unstable @entity2 ( @entity2 ) of the elbow. However, little information is available comparing the anticipated results from the host of techniques. In this investigation, clinical and radiographic resolution as well as return to sports rates were assessed in adolescent @entity0 following loose body (LB) removal and drilling/microfracture of grade IV lesions. METHODS: We reviewed 21 adolescents treated with LB removal and drilling/microfracture for grade IV elbow @entity2 . @entity0 with additional elbow pathology, prior elbow surgery, or <1 year follow-up were excluded. Clinical resolution was defined as resolution of tenderness and radiographic resolution as resolution of @entity1 on magnetic resonance imaging (MRI). Return to sport rates and Timmerman scores were assessed. Mean clinical and MRI follow-up times were 2.2  1.19 and 2.4  1.54 years, respectively. Clinical and radiographic parameters associated with clinical and/or radiographic resolution or return to sports were determined using penalized likelihood logistic regression. Wilcoxon signed-rank tests were used to evaluate the change in range of motion and in Timmerman scores. RESULTS: Fifteen (71.4%) @entity0 had either clinical or radiographic resolution at most recent follow-up. Nine (50%) had complete resolution on MRI, whereas 13 (61.9%) were nontender at their follow-up. Four @entity0 with recurrent LBs underwent revision surgery. There were no complications in the 21 index procedures. Eighteen (85.7%) @entity0 returned to any sport, whereas 14 (66. 7%) returned to their primary sport. Elbow flexion and extension improved by medians of 12 and 21 degrees, respectively (P=0.002, 0.01). Timmerman scores improved by a median of 30 (P=0.001). Shorter duration of symptoms correlated with @entity2 (P=0.03) and with improved clinical or radiographic resolution and return to sport rates. CONCLUSIONS: The majority of @entity0 with grade IV elbow @entity2 achieves clinical and/or radiographic resolution and return to sports 2 years after LB removal and drilling/microfracture. Recurrence may be seen, however, and further investigation is needed to assess the efficacy of this technique compared with other treatment strategies. LEVEL OF EVIDENCE: Level IV.

title: Early Results of Drilling and/or Microfracture for Grade IV XXXX .

answer: @entity2


abstract: BACKGROUND AND OBJECTIVES: @entity6 has been consistently associated with high mortality rate in peritoneal dialysis. However, studies investigating if @entity6 is acting as a surrogate marker of comorbidities or has a direct effect in the risk for mortality have not been studied. Thus, the aim of this study was to analyze the effect of @entity6 on overall and cause-specific mortality. DESIGN, SETTING, @entity0 AND MEASUREMENTS: This is an analysis of BRAZPD II, a nationwide prospective cohort study. All @entity0 on @entity7 for longer than 90 days with measured serum @entity5 levels were used to verify the association of @entity6 with overall and cause-specific mortality using a propensity match score to reduce selection bias. In addition, competing risks were also taken into account for the analysis of cause-specific mortality. RESULTS: There was a U-shaped relationship between time-averaged serum @entity5 and all-cause mortality of @entity7 @entity0 . @entity1 was the main cause of @entity2 in the normokalemic group with 133 events (41.8%) followed by @entity3 , n=105 (33.0%). @entity6 was associated with a 49% increased risk for CV mortality after adjustments for covariates and the presence of competing risks (SHR 1.49; CI95% 1.01-2.21). In contrast, in the group of @entity0 with K <3.5mEq/L, @entity3 were the main cause of @entity2 with 43 events (44.3%) followed by @entity1 (n=36; 37.1%). For @entity3 the SHR was 2.19 (CI95% 1.52-3.14) while for @entity4 was SHR 1.09 (CI95% 0.47-2.49). CONCLUSIONS: @entity6 had a significant impact on overall, cardiovascular and infectious mortality even after adjustments for competing risks. The causative nature of this association suggested by our study raises the need for intervention studies looking at the effect of @entity5 supplementation on clinical outcomes of @entity7 @entity0 .

title: Low Serum XXXX Levels Increase the Infectious-Caused Mortality in Peritoneal Dialysis @entity0 : A Propensity-Matched Score Study.

answer: @entity5


abstract: BACKGROUND AND OBJECTIVES: @entity6 has been consistently associated with high mortality rate in peritoneal dialysis. However, studies investigating if @entity6 is acting as a surrogate marker of comorbidities or has a direct effect in the risk for mortality have not been studied. Thus, the aim of this study was to analyze the effect of @entity6 on overall and cause-specific mortality. DESIGN, SETTING, @entity0 AND MEASUREMENTS: This is an analysis of BRAZPD II, a nationwide prospective cohort study. All @entity0 on @entity7 for longer than 90 days with measured serum @entity5 levels were used to verify the association of @entity6 with overall and cause-specific mortality using a propensity match score to reduce selection bias. In addition, competing risks were also taken into account for the analysis of cause-specific mortality. RESULTS: There was a U-shaped relationship between time-averaged serum @entity5 and all-cause mortality of @entity7 @entity0 . @entity1 was the main cause of @entity2 in the normokalemic group with 133 events (41.8%) followed by @entity3 , n=105 (33.0%). @entity6 was associated with a 49% increased risk for CV mortality after adjustments for covariates and the presence of competing risks (SHR 1.49; CI95% 1.01-2.21). In contrast, in the group of @entity0 with K <3.5mEq/L, @entity3 were the main cause of @entity2 with 43 events (44.3%) followed by @entity1 (n=36; 37.1%). For @entity3 the SHR was 2.19 (CI95% 1.52-3.14) while for @entity4 was SHR 1.09 (CI95% 0.47-2.49). CONCLUSIONS: @entity6 had a significant impact on overall, cardiovascular and infectious mortality even after adjustments for competing risks. The causative nature of this association suggested by our study raises the need for intervention studies looking at the effect of @entity5 supplementation on clinical outcomes of @entity7 @entity0 .

title: Low Serum @entity5 Levels Increase the Infectious-Caused Mortality in Peritoneal Dialysis XXXX : A Propensity-Matched Score Study.

answer: @entity0


abstract: UNASSIGNED: @entity2 following arthroscopic anterior cruciate ligament (ACL) reconstruction of the knee are rare. @entity3 around the knee have historically been reported more commonly, with reconstructive procedures occurring more posteriorly, such as posterior cruciate ligament (PCL) reconstruction. The authors present a report of sequelae following a @entity1 in an 18-year-old female soccer player who underwent ACL reconstruction using an ipsilateral autologous hamstring graft along with a medial meniscal repair and developed immediate @entity4 of the popliteal artery responding to sustained balloon angioplasty. Seven weeks postoperatively, she developed foot paresthesias and was noted to have a 3.5*3.1*1.3-cm @entity5 of her popliteal artery. She underwent popliteal artery bypass with reverse saphenous vein autograft and had an uneventful recovery. This case highlights the importance of prolonged follow-up and maintaining a high degree of @entity2 , even after routine arthroscopic knee procedures. In addition to maintaining close and extended follow-up, the authors agree with other authors' suggestions that urgent computed tomography angiogram be obtained to evaluate the vascular tree in a @entity0 presenting with a cold, @entity6 after routine arthroscopic knee procedures. In this particular case, angiography of the uninvolved side also proved useful in identifying the @entity0 's aberrant vascular anatomy and may be useful in @entity0 with bilateral aberrant vascular anatomy to better facilitate interpretation of the injured side. To the author's knowledge, this is the first case of popliteal artery @entity4 initially responding to sustained angioplasty with the delayed development of a @entity5 . [Orthopedics. 2015; 38(6):e543-e546.].

title: Delayed XXXX of the Popliteal Artery Following ACL Reconstruction.

answer: @entity5


abstract: OBJECTIVES: As our healthcare system moves toward bundling payments, orthopaedic @entity1 surgeons will be increasingly benchmarked on perioperative complications. We therefore sought to determine financial risks under bundled payments by identifying adverse event rates for (1) orthopaedic @entity1 @entity0 compared with general orthopaedic @entity0 and (2) based on anatomic region and (3) to identify @entity0 factors associated with complications. DESIGN: Prospective. SETTING: Multicenter. @entity0 / @entity0 : A total of 146,773 orthopaedic @entity0 (22,361 @entity1 ) from 2005 to 2011 NSQIP data were identified. INTERVENTIONS: Minor and major adverse events, demographics, surgical variables, and @entity0 comorbidities were collected. MAIN OUTCOME MEASUREMENTS: Multivariate regressions determined significant risk factors for the development of complications. RESULTS: The @entity2 rate in the @entity1 group was 11.4% (2554/22,361) versus 4.1% (5137/124,412) in the general orthopaedic group (P = 0.001). When controlling for all variables, @entity1 was a risk factor for developing complications [odds ratio (OR): 1.69, 95% confidence interval (CI): 1.57-1.81]. After controlling for several @entity0 factors, hip and pelvis @entity0 were 4 times more likely to develop any perioperative @entity2 than @entity4 @entity0 (OR: 3.79, 95% CI: 3.01-4.79, P = 0.01). Lower @entity3 @entity0 are 3 times more likely to develop any @entity2 versus @entity4 @entity0 (OR: 2.82, 95% CI: 2.30-3.46, P = 0.01). CONCLUSIONS: Our study is the first to show that orthopaedic @entity1 @entity0 are 2 times more likely than general orthopaedic @entity0 to sustain complications, despite controlling for identical risk factors. There is also an alarming difference in @entity2 rates among anatomic regions. Orthopaedic @entity1 surgeons will face increased financial risk with bundled payments. LEVEL OF EVIDENCE: Prognostic Level II. See Instructions for Authors for a complete description of levels of evidence.

title: Adverse Events in Orthopaedics: Is XXXX More Risky? An Analysis of the NSQIP Data.

answer: @entity1


abstract: BACKGROUND: Interleukin (IL)-12 is a pro-inflammatory cytokine that mediates T-helper type 1 responses and cytotoxic T-cell activation, contributing to its utility as anti- @entity1 agent. Systemic administration of IL-12 often results in unacceptable @entity2 ; therefore, strategies to direct delivery of IL-12 to @entity1 are under investigation. The objective of this study was to assist the preclinical development of NHS-IL12, an immunocytokine consisting of an antibody, which targets @entity1 regions, linked to IL-12. Specifically this study sought to evaluate the safety, serum pharmacokinetics, anti- @entity1 activity, and immune modulation of NHS-IL12 in @entity3 with naturally occurring @entity1 . METHODOLOGY/PRINCIPAL FINDINGS: A rapid dose-escalation study of NHS-IL12 administered subcutaneously to @entity3 with @entity4 was conducted through the Comparative Oncology Trials Consortium (COTC). Eleven @entity3 were enrolled in four dose-escalation cohorts; thereafter, an additional seven @entity3 were treated at the defined tolerable dose of 0.8 mg/m2. The expanded cohort at this fixed dose (ten @entity3 in total) was accrued for further pharmacokinetics and pharmacodynamics assessment. NHS-IL12 levels, serum cytokine concentrations, and peripheral blood mononuclear cell characterization (post-treatment) and draining lymph node immune profiling, and @entity1 biopsies (pre- and post-treatment) were collected. Adverse events included @entity5 , liver enzymopathies, fever, and @entity6 . Correlation between interferon (IFN)-y induction, adverse events, and NHS-IL12 exposure (maximum concentration and area under the concentration-time curve) were dose-dependent. Serum @entity7 levels and intratumoral CD8+ populations increased after treatment. Partial responses, according to Response Evaluation Criteria in @entity1 (RECIST) criteria, were observed in two @entity3 treated with NHS-IL12 0.8 mg/m2 and 1.6 mg/m2. CONCLUSIONS/SIGNIFICANCE: NHS-IL12 was administered safely to @entity3 with @entity4 and both immunologic and clinical activity was observed. This study successfully defined a narrow therapeutic window for systemic delivery of NHS-IL12 via the subcutaneous route. Results will inform the design and implementation of first-in- @entity0 clinical trials of NHS-IL12 in @entity1 @entity0 .

title: Defining the Pharmacodynamic Profile and Therapeutic Index of NHS-IL12 Immunocytokine in @entity3 with XXXX .

answer: @entity4


abstract: BACKGROUND: Interleukin (IL)-12 is a pro-inflammatory cytokine that mediates T-helper type 1 responses and cytotoxic T-cell activation, contributing to its utility as anti- @entity1 agent. Systemic administration of IL-12 often results in unacceptable @entity2 ; therefore, strategies to direct delivery of IL-12 to @entity1 are under investigation. The objective of this study was to assist the preclinical development of NHS-IL12, an immunocytokine consisting of an antibody, which targets @entity1 regions, linked to IL-12. Specifically this study sought to evaluate the safety, serum pharmacokinetics, anti- @entity1 activity, and immune modulation of NHS-IL12 in @entity3 with naturally occurring @entity1 . METHODOLOGY/PRINCIPAL FINDINGS: A rapid dose-escalation study of NHS-IL12 administered subcutaneously to @entity3 with @entity4 was conducted through the Comparative Oncology Trials Consortium (COTC). Eleven @entity3 were enrolled in four dose-escalation cohorts; thereafter, an additional seven @entity3 were treated at the defined tolerable dose of 0.8 mg/m2. The expanded cohort at this fixed dose (ten @entity3 in total) was accrued for further pharmacokinetics and pharmacodynamics assessment. NHS-IL12 levels, serum cytokine concentrations, and peripheral blood mononuclear cell characterization (post-treatment) and draining lymph node immune profiling, and @entity1 biopsies (pre- and post-treatment) were collected. Adverse events included @entity5 , liver enzymopathies, fever, and @entity6 . Correlation between interferon (IFN)-y induction, adverse events, and NHS-IL12 exposure (maximum concentration and area under the concentration-time curve) were dose-dependent. Serum @entity7 levels and intratumoral CD8+ populations increased after treatment. Partial responses, according to Response Evaluation Criteria in @entity1 (RECIST) criteria, were observed in two @entity3 treated with NHS-IL12 0.8 mg/m2 and 1.6 mg/m2. CONCLUSIONS/SIGNIFICANCE: NHS-IL12 was administered safely to @entity3 with @entity4 and both immunologic and clinical activity was observed. This study successfully defined a narrow therapeutic window for systemic delivery of NHS-IL12 via the subcutaneous route. Results will inform the design and implementation of first-in- @entity0 clinical trials of NHS-IL12 in @entity1 @entity0 .

title: Defining the Pharmacodynamic Profile and Therapeutic Index of NHS-IL12 Immunocytokine in XXXX with @entity4 .

answer: @entity3


abstract: The clinical features of @entity6 ( @entity6 ) were studied statistically in 106 cases of @entity6 . The point of the @entity2 at which the @entity0 could best see the targets was detected in some @entity0 . The effects of superior colliculectomy on their visual disturbance and the mechanism will be discussed. The study population comprises 106 @entity0 , 79 males and 27 females, aged from one to 64 (mean 19.4 years). @entity0 with jerky type classified on @entity5 were found in 53 cases (50%), pendular type in 39 cases (37%), and mixed type in 14 cases (13%). @entity0 with jerky type showed significantly good visual acuity (mean 0.69 +/- 0.31, p less than 0.005). They showed significant abnormalities during pregnancy and delivery (p less than 0.01) and had a neutral point (p less than 0.01). @entity0 with pendular type, on the other hand, showed poor visual acuity (mean 0.26 +/- 0.30) and had significant frequency of family history (p less than 0.05), head @entity3 (p less than 0.01) and strabismus (p less than 0.01). Thirteen cases (12%) had @entity4 which involved the retina, @entity1 and optic nerve. Visual function was elaborated on such parameters of @entity5 as perception, peak variation and plateau time. Perception, which means the ability to detect the dim flashes during the appearance of the @entity2 , was manifested by pushing a button when @entity0 could detect flashes presented at random on the screen. At the turning point from the quick phase to the slow phase, the detection was executed most successfully. It is thought that in @entity6 , a target is usually gazed upon at a point, changing the direction from the quick phase to the slow phase.(ABSTRACT TRUNCATED AT 250 WORDS)

title: [A study of visual function in XXXX --mechanism of visual improvement after stereotactic superior colliculectomy].

answer: @entity6


abstract: One-hundred sixty-seven @entity0 with 190 carotid arteries (109 asymptomatic) demonstrating 50-99% stenosis by arteriography (80), duplex scanning, or other noninvasive techniques were followed from 1-84 months (mean 24.2) for evidence of @entity6 , transient @entity3 attacks, or vertebrobasilar symptoms. Thirty-nine arteries (20.5%) were symptomatic at last follow-up, including 13 (6.8%) producing @entity4 . Twenty-eight sides underwent carotid endarterectomy, 16 for symptomatic lesions at a mean interval of 14.5 months after the initial diagnostic study, with no @entity2 . Twenty-seven @entity0 (16.2%) died, eight from @entity4 (30%), and 12 from cardiac causes (44%). In initially symptomatic sides, the incidence of any subsequent neurologic event (28.7%) or @entity4 /transient @entity3 attack (25%) was significantly greater than in asymptomatic arteries (14.6% and 12%, respectively) (p less than .05). Carotid arteries with greater than 80% stenosis by arteriography and duplex scanning had a 46% incidence of further symptoms and 41.6% @entity4 /transient @entity3 attack rate compared to 19.6% and 15%, respectively, in arteries with less than 80% stenosis (p less than .01). Cumulative life table analysis at 12, 24 and 36 months showed greater than 80% stenosed arteries to have @entity4 /transient @entity3 attack free rates of 69%, 50.5%, and 21.6% compared to 91%, 83.7%, and 76% for arteries with less than 80% stenosis (p less than .05). At a mean follow-up of over two years, nonoperated @entity5 (greater than 50%) carries a 20.5% risk of @entity1 and a 6.8% risk of @entity4 , 61.5% of @entity4 being fatal. Symptomatic @entity5 had a significantly greater incidence of ensuing neurologic events than asymptomatic arteries.(ABSTRACT TRUNCATED AT 250 WORDS)

title: Natural history of nonoperated, significant XXXX .

answer: @entity5


abstract: UNASSIGNED: Purpose To evaluate accuracy and interobserver variability with the use of the Prostate Imaging Reporting and Data System (PI-RADS) version 2.0 for detection of @entity1 at multiparametric magnetic resonance (MR) imaging in a biopsy-na  ve @entity0 population. Materials and Methods This retrospective HIPAA-compliant study was approved by the local ethics committee, and written informed consent was obtained from all @entity0 for use of their imaging and histopathologic data in future research studies. In 101 biopsy-na  ve @entity0 with elevated prostate-specific antigen levels who underwent multiparametric MR imaging of the prostate and subsequent transrectal ultrasonography (US)-MR imaging fusion-guided biopsy, suspicious lesions detected at multiparametric MR imaging were scored by five readers who were blinded to pathologic results by using to the newly revised PI-RADS and the scoring system developed in-house. Interobserver agreement was evaluated by using k statistics, and the correlation of pathologic results with each of the two scoring systems was evaluated by using the Kendall    correlation coefficient. Results Specimens of 162 lesions in 94 @entity0 were sampled by means of transrectal US-MR imaging fusion biopsy. Results for 87 (54%) lesions were positive for @entity1 . Kendall    values with the PI-RADS and the in-house-developed scoring system, respectively, at T2-weighted MR imaging in the peripheral zone were 0.51 and 0.17 and in the transitional zone, 0.45 and -0.11; at diffusion-weighted MR imaging, 0.42 and 0.28; at dynamic contrast material-enhanced MR imaging, 0.23 and 0.24, and overall suspicion scores were 0.42 and 0.49. Median k scores among all possible pairs of readers for PI-RADS and the in-house-developed scoring system, respectively, for T2-weighted MR images in the peripheral zone were 0.47 and 0.15; transitional zone, 0.37 and 0.07; diffusion-weighted MR imaging, 0.41 and 0.57; dynamic contrast-enhanced MR imaging, 0.48 and 0.41; and overall suspicion scores, 0.46 and 0.55. Conclusion Use of the revised PI-RADS provides moderately reproducible MR imaging scores for detection of clinically relevant disease. (  ) RSNA, 2015 Online supplemental material is available for this article.

title: XXXX : Interobserver Agreement and Accuracy with the Revised Prostate Imaging Reporting and Data System at Multiparametric MR Imaging.

answer: @entity1


abstract: BACKGROUND: The aims of this study were to describe the basic parameters of adult @entity0 with acute community-onset @entity7 or campylobacteriosis responsible for more than 90 % of all cases of community-onset @entity3 in the Czech Republic, and, according to the results of this analysis, to update the diagnostic and therapeutic algorithms. MATERIALS AND METHODS: The data were collected retrospectively between January 1, 2011 and December 31, 2013. @entity0 with systemic signs of @entity2 having at least 2 signs of @entity4 ( @entity4 ) or with elevated serum @entity6 levels (more than 0.5 ng/ml) were classified as being at risk for the invasive form of the disease. The remaining @entity0 were classified as having the simple intestinal form of the disease. @entity0 with community-onset post-antibiotic @entity3 were excluded. The data were statistically processed. RESULTS: The following clinical factors were statistically significantly correlated with the high-risk form of the disease: duration of illness of less than 3 days before admission and any of the following (some of them are part of the @entity4 classification), even after being adjusted for age: body temperature above 38   C, peripheral blood white cell count (WBC) above 12 * 10   /l, neutrophil count above 9 * 10   /l and @entity5 level above 150 mg/l. The risk form of the disease occurred in 60 cases (18.7 %). The mean WBC was 9.4 * 10   /l (median, 8.4; range, 1.7-89.0). The WBC within the normal range was seen in 194 cases (60.4 %). The mean @entity5 level was 92.9 mg/l (median, 77.0; range, 1.0-342.0). An elevated @entity6 level was seen in 21 @entity0 ; the marker was not routinely measured. Positive blood culture results were obtained in 2 @entity0 with @entity7 ; the examination was not routinely performed. There were 34 @entity0 (10.6 %) with documented immune system dysfunction; the risk form of @entity7 or campylobacteriosis was seen in only 11 of them (3.4 %). A total of 306 @entity0 (95.3 %) were treated with antibiotics; the mean duration of antibiotic therapy was 8.7 days (median, 7; range, 2-31). CONCLUSIONS: Antibiotic treatment in @entity7 /campylobacteriosis should not be indicated only due to elevated @entity5 levels but rather after comprehensive evaluation of the duration of symptoms, individual risk factors and dynamic changes in markers of @entity1 . Blood culture tests should be carried out more frequently.

title: [When should empirical antibiotic therapy be indicated in acute community-onset XXXX of suspected bacterial etiology].

answer: @entity3


abstract: The present study was designed to examine the question of whether or not there is a natriuretic hormonal substance involved in the renal regulation of @entity5 balance. For this purpose, procedures for concentration and fractionation of plasma and urine samples and a sensitive bioassay for demonstrating changes in renal @entity5 excretion were developed. The natriuretic assay utilized @entity1 with mild @entity6 which were maintained in salt and water balance. Using these approaches a natriuretic humoral substance was demonstrated in plasma and urine from normal @entity0 and @entity3 , and in @entity0 with @entity4 or essential @entity2 . It seems likely that this substance participates in day to day regulation of @entity5 balance because it was not detectable in @entity5 -depleted subjects and it consistently appeared in the @entity5 -loaded subjects. The hormonal agent may not act immediately and its activity can be apparent for up to 3 hr. Full expression of its activity requires that the assay animals be appropriately volume expanded. This suggests that the increases in @entity5 excretion mediated by this hormonal substance depend in part on the coparticipation of other physical and perhaps humoral factors. This natriuretic substance appears to be of large molecular weight or carried by a large molecule. The data suggest that it acts, at least in part, to block @entity5 reabsorption in a more distal portion of the tubule.

title: Natriuretic activity in plasma and urine of salt-loaded @entity0 and XXXX .

answer: @entity3


abstract: The present study was designed to examine the question of whether or not there is a natriuretic hormonal substance involved in the renal regulation of @entity5 balance. For this purpose, procedures for concentration and fractionation of plasma and urine samples and a sensitive bioassay for demonstrating changes in renal @entity5 excretion were developed. The natriuretic assay utilized @entity1 with mild @entity6 which were maintained in salt and water balance. Using these approaches a natriuretic humoral substance was demonstrated in plasma and urine from normal @entity0 and @entity3 , and in @entity0 with @entity4 or essential @entity2 . It seems likely that this substance participates in day to day regulation of @entity5 balance because it was not detectable in @entity5 -depleted subjects and it consistently appeared in the @entity5 -loaded subjects. The hormonal agent may not act immediately and its activity can be apparent for up to 3 hr. Full expression of its activity requires that the assay animals be appropriately volume expanded. This suggests that the increases in @entity5 excretion mediated by this hormonal substance depend in part on the coparticipation of other physical and perhaps humoral factors. This natriuretic substance appears to be of large molecular weight or carried by a large molecule. The data suggest that it acts, at least in part, to block @entity5 reabsorption in a more distal portion of the tubule.

title: Natriuretic activity in plasma and urine of salt-loaded XXXX and @entity3 .

answer: @entity0


abstract: Previous studies have demonstrated symptoms and mediator release occurring as long as 11 h after nasal challenge with antigen in selected @entity0 subjects. Pretreatment with systemic @entity4 reduced symptoms and mediators including @entity1 , @entity6 -esterase activity, and kinins. The aims of the present study were to characterize the cell influx during the late-phase response to antigen challenge and to determine the effect of pretreatment with systemic @entity4 on this response. We examined cytospin slides of nasal washings obtained before and hourly for 11 h after nasal antigen challenge in 10 asymptomatic @entity0 subjects with a history of @entity5 and 5 normal, nonallergic subjects. Allergic subjects received oral @entity3 (20 mg 3 times a day) or placebo in a random, double-blind crossover manner for 2 days before each of 2 challenges 1 month apart. On placebo days, a mixed cell influx occurred in @entity0 subjects during the late response that was 50-fold greater than the cell influx in the nonallergic control subjects (p less than 0.005). During the first 3 h after antigen challenge, eosinophils (p less than 0.005), but not neutrophils or mononuclear cells, were observed. During the late phase (4 to 11 h), neutrophils, eosinophils, and mononuclear cells were all increased. Oral @entity2 pretreatment blocked the influx of eosinophils (p less than 0.005), but not that of other cells. These data demonstrate an inflammatory cell influx associated with the nasal late-phase response and suggest an important pathogenetic role for the eosinophil.(ABSTRACT TRUNCATED AT 250 WORDS)

title: The influx of inflammatory cells into nasal washings during the late response to antigen challenge. Effect of systemic XXXX pretreatment.

answer: @entity2


abstract: BACKGROUND: Detection of @entity1 in primary care is a complex issue. Distinctions between ' @entity2 and @entity1 depend on how disorder is conceptualized. Our aim was to explore two different conceptualizations by examining @entity0 ' scores on one-dimensional @entity3 measures and scores on the Four Dimensional Symptom Questionnaire (4DSQ), a measure that uniquely has separate dimensions for general distress and @entity3 . METHODS: This was a cross sectional study of 487 primary care @entity0 attending general clinics in Hampshire, UK. @entity0 completed the 4DSQ, @entity0 Health Questionnaire-9 (PHQ-9), General Health Questionnaire-12 (GHQ-12) and the Hospital Anxiety and @entity3 Scale (HADS) whilst in the waiting room. RESULTS: The 4DSQ classified 26% (126/485) of @entity0 as having heightened distress levels and 8% (38/468) as possible cases of @entity3 . Casesness was consistently higher across the one-dimensional measures (PHQ-9: 16%, GHQ-12: 28%, HADS-D: 13%). Of those @entity0 deemed possible cases by the PHQ-9 (>= 10), the 4DSQ classified 91% (71/78) as having heightened distress and 44% (32/72) as possible cases of @entity3 . LIMITATIONS: The sample was predominately older and white, which may limit generalizability of the findings to more diverse @entity0 groups. There are limits to self-report measures in the assessment of complex diagnostic issues. CONCLUSIONS: Inclusion of a distinct general distress dimension alongside a dimension focusing on specific @entity3 symptomatology lowered the number of primary care @entity0 classified as possible cases of disorder. This view of symptoms may have implications for the targeting of existing treatments, and may be useful in guiding the development of novel self-management interventions.

title: XXXX and @entity1 in primary care attenders: A cross sectional study of the four-dimensional symptom questionnaire (4DSQ).

answer: @entity2


abstract: BACKGROUND: Detection of @entity1 in primary care is a complex issue. Distinctions between ' @entity2 and @entity1 depend on how disorder is conceptualized. Our aim was to explore two different conceptualizations by examining @entity0 ' scores on one-dimensional @entity3 measures and scores on the Four Dimensional Symptom Questionnaire (4DSQ), a measure that uniquely has separate dimensions for general distress and @entity3 . METHODS: This was a cross sectional study of 487 primary care @entity0 attending general clinics in Hampshire, UK. @entity0 completed the 4DSQ, @entity0 Health Questionnaire-9 (PHQ-9), General Health Questionnaire-12 (GHQ-12) and the Hospital Anxiety and @entity3 Scale (HADS) whilst in the waiting room. RESULTS: The 4DSQ classified 26% (126/485) of @entity0 as having heightened distress levels and 8% (38/468) as possible cases of @entity3 . Casesness was consistently higher across the one-dimensional measures (PHQ-9: 16%, GHQ-12: 28%, HADS-D: 13%). Of those @entity0 deemed possible cases by the PHQ-9 (>= 10), the 4DSQ classified 91% (71/78) as having heightened distress and 44% (32/72) as possible cases of @entity3 . LIMITATIONS: The sample was predominately older and white, which may limit generalizability of the findings to more diverse @entity0 groups. There are limits to self-report measures in the assessment of complex diagnostic issues. CONCLUSIONS: Inclusion of a distinct general distress dimension alongside a dimension focusing on specific @entity3 symptomatology lowered the number of primary care @entity0 classified as possible cases of disorder. This view of symptoms may have implications for the targeting of existing treatments, and may be useful in guiding the development of novel self-management interventions.

title: @entity2 and XXXX in primary care attenders: A cross sectional study of the four-dimensional symptom questionnaire (4DSQ).

answer: @entity1


abstract: BACKGROUND: The aim of this study was to investigate the clinical efficacy of B-mode ultrasound-guided retroperitoneal and abdominal catheter treatment of severe acute @entity2 . METHODS: A retrospective analysis was performed, regarding 68 @entity0 diagnosed with severe acute @entity2 in our hospital from May 2012 to May 2014. @entity0 were divided into an observation group (N.=38) and a control group (N.=30). @entity0 in the control group received conventional drug therapy and were given CT-guided catheter or surgical treatment when necessary. The observation group received conventional drug therapy + B-mode ultrasound-guided retroperitoneal and abdominal catheter drainage and lavage. The clinical efficacy and complication rate differences of the two groups of @entity0 were compared and analyzed. RESULTS: The total efficacy rates in the observation group were significantly higher than in the control group (P<0.05). The serum @entity1 levels of the observation group were obviously higher than that of the control group while their CRP levels and APACHE II scores were significantly lower (P<0.05). Complications were significantly lower in the observation group than in the control group (P<0.05). CONCLUSIONS: B-mode ultrasound-guided biopsy for retroperitoneal and abdominal subcutaneous catheter drainage and lavage treatment of severe acute @entity2 may improve the clinical effect and reduce complications.

title: Clinical study of B-mode ultrasound-guided retroperitoneal and abdominal catheter treatment of severe acute XXXX .

answer: @entity2


abstract: OBJECTIVES: To evaluate changes in annual blood transfusion requirements and complications after splenectomy in @entity0 with @entity3 . METHODS: Forty post-splenectomy b-thalassemic @entity0 aged 8-33  y, receiving regular blood transfusions and chelation therapy were included and non transfusion dependant @entity0 were excluded from this retrospective cross-sectional study. Details about their surgery, transfusion requirements, and platelet levels were recorded on a standard proforma. All @entity0 underwent a B-mode and color-coded duplex sonography of the hepatoportal system during the study period. RESULTS: The average ferritin level in the year prior to the study was 4432 mcg/L (range 480-12,200 mcg/L). The annual blood transfusion requirement in the first year and 5  y post splenectomy [mean        SD (138.41        90.38  ml/kg/y); (116        41.44  ml/kg/y)] were significantly different from requirements before splenectomy [(mean        SD) 294.85        226  ml/kg/y; p value <0.001]. There was a significant rise in platelet counts within 24  h post splenectomy with a mean rise of 4,51,000/mm(3) (p value   <   0.001). During the follow up period, infections were noted in 50  % of @entity0 , with @entity1 (18.75  %) being the most common. Doppler study of the portal system in one case showed @entity2 . CONCLUSIONS: A significant sustained fall in annual blood transfusion requirement and a rise in platelet counts occurred post-splenectomy. Increase in annual blood transfusion requirement should be investigated to find the cause.

title: Post Splenectomy Outcome in XXXX .

answer: @entity3


abstract: UNASSIGNED: @entity5 , an alkaloid extracted from medicinal plants of the genus Sophora, has a wide range of pharmacological effects. Previous studies have revealed that @entity5 can inhibit proliferation and metastasis of @entity1 cells through reducing @entity3 ( @entity3 ) mRNA expression. However, the expression of @entity3 in @entity2 is significantly higher than that in normal ovaries. Furthermore, the expression of microRNA  -29b ( @entity4 ) in @entity2 is significantly lower than that in normal ovaries. Therefore, @entity3 and @entity4 are @entity1 suppressor factors involved in @entity2 . To evaluate the anti- @entity1 effects of @entity5 the @entity0 @entity2 cell line was treated with @entity5 at the concentrations of 0, 0.5, 1 and 2  mg/ml. Assessment of the proliferation and apoptosis of @entity0 cells showed that @entity5 had an inhibitory effect on @entity2 cells. Furthermore, @entity5 decreased the protein levels of @entity3 and increased the expression levels of @entity4 in @entity0 cells. Through transfection of @entity4 precursor into @entity0 cells, it was demonstrated that @entity4 regulated @entity3 expression in @entity0 cells. In addition, anti  - @entity4 antibodies were used to verify that the apoptotic effect of @entity5 was due to upregulating @entity4 and downregulating @entity3 expression. These results showed that @entity5 suppresses the proliferation and facilitates apoptosis of @entity0 @entity2 cells through upregulating @entity4 and downregulating @entity3 expression.

title: XXXX suppresses proliferation and facilitates apoptosis of @entity0 @entity2 cells through upregulating microRNA  -29b and downregulating @entity3 expression.

answer: @entity5


abstract: UNASSIGNED: @entity5 , an alkaloid extracted from medicinal plants of the genus Sophora, has a wide range of pharmacological effects. Previous studies have revealed that @entity5 can inhibit proliferation and metastasis of @entity1 cells through reducing @entity3 ( @entity3 ) mRNA expression. However, the expression of @entity3 in @entity2 is significantly higher than that in normal ovaries. Furthermore, the expression of microRNA  -29b ( @entity4 ) in @entity2 is significantly lower than that in normal ovaries. Therefore, @entity3 and @entity4 are @entity1 suppressor factors involved in @entity2 . To evaluate the anti- @entity1 effects of @entity5 the @entity0 @entity2 cell line was treated with @entity5 at the concentrations of 0, 0.5, 1 and 2  mg/ml. Assessment of the proliferation and apoptosis of @entity0 cells showed that @entity5 had an inhibitory effect on @entity2 cells. Furthermore, @entity5 decreased the protein levels of @entity3 and increased the expression levels of @entity4 in @entity0 cells. Through transfection of @entity4 precursor into @entity0 cells, it was demonstrated that @entity4 regulated @entity3 expression in @entity0 cells. In addition, anti  - @entity4 antibodies were used to verify that the apoptotic effect of @entity5 was due to upregulating @entity4 and downregulating @entity3 expression. These results showed that @entity5 suppresses the proliferation and facilitates apoptosis of @entity0 @entity2 cells through upregulating @entity4 and downregulating @entity3 expression.

title: @entity5 suppresses proliferation and facilitates apoptosis of @entity0 @entity2 cells through upregulating microRNA  -29b and downregulating XXXX expression.

answer: @entity3


abstract: UNASSIGNED: @entity5 , an alkaloid extracted from medicinal plants of the genus Sophora, has a wide range of pharmacological effects. Previous studies have revealed that @entity5 can inhibit proliferation and metastasis of @entity1 cells through reducing @entity3 ( @entity3 ) mRNA expression. However, the expression of @entity3 in @entity2 is significantly higher than that in normal ovaries. Furthermore, the expression of microRNA  -29b ( @entity4 ) in @entity2 is significantly lower than that in normal ovaries. Therefore, @entity3 and @entity4 are @entity1 suppressor factors involved in @entity2 . To evaluate the anti- @entity1 effects of @entity5 the @entity0 @entity2 cell line was treated with @entity5 at the concentrations of 0, 0.5, 1 and 2  mg/ml. Assessment of the proliferation and apoptosis of @entity0 cells showed that @entity5 had an inhibitory effect on @entity2 cells. Furthermore, @entity5 decreased the protein levels of @entity3 and increased the expression levels of @entity4 in @entity0 cells. Through transfection of @entity4 precursor into @entity0 cells, it was demonstrated that @entity4 regulated @entity3 expression in @entity0 cells. In addition, anti  - @entity4 antibodies were used to verify that the apoptotic effect of @entity5 was due to upregulating @entity4 and downregulating @entity3 expression. These results showed that @entity5 suppresses the proliferation and facilitates apoptosis of @entity0 @entity2 cells through upregulating @entity4 and downregulating @entity3 expression.

title: @entity5 suppresses proliferation and facilitates apoptosis of @entity0 XXXX cells through upregulating microRNA  -29b and downregulating @entity3 expression.

answer: @entity2


abstract: UNASSIGNED: @entity5 , an alkaloid extracted from medicinal plants of the genus Sophora, has a wide range of pharmacological effects. Previous studies have revealed that @entity5 can inhibit proliferation and metastasis of @entity1 cells through reducing @entity3 ( @entity3 ) mRNA expression. However, the expression of @entity3 in @entity2 is significantly higher than that in normal ovaries. Furthermore, the expression of microRNA  -29b ( @entity4 ) in @entity2 is significantly lower than that in normal ovaries. Therefore, @entity3 and @entity4 are @entity1 suppressor factors involved in @entity2 . To evaluate the anti- @entity1 effects of @entity5 the @entity0 @entity2 cell line was treated with @entity5 at the concentrations of 0, 0.5, 1 and 2  mg/ml. Assessment of the proliferation and apoptosis of @entity0 cells showed that @entity5 had an inhibitory effect on @entity2 cells. Furthermore, @entity5 decreased the protein levels of @entity3 and increased the expression levels of @entity4 in @entity0 cells. Through transfection of @entity4 precursor into @entity0 cells, it was demonstrated that @entity4 regulated @entity3 expression in @entity0 cells. In addition, anti  - @entity4 antibodies were used to verify that the apoptotic effect of @entity5 was due to upregulating @entity4 and downregulating @entity3 expression. These results showed that @entity5 suppresses the proliferation and facilitates apoptosis of @entity0 @entity2 cells through upregulating @entity4 and downregulating @entity3 expression.

title: @entity5 suppresses proliferation and facilitates apoptosis of XXXX @entity2 cells through upregulating microRNA  -29b and downregulating @entity3 expression.

answer: @entity0


abstract: BACKGROUND: @entity2 is considered one of the major causes of protein-energy wasting in @entity1 ( @entity1 ) @entity0 . It is unclear whether dietary interventions can impact nutritional status and quality of life in @entity1 @entity0 with elevated @entity4 ( @entity4 ) levels. Therefore, we examined the hypothesis that supervised intra-dialysis protein supplementation in @entity1 @entity0 with elevated plasma @entity4 will improve protein stores and quality of life. METHODS: A 24  week, two phase, longitudinal, single center, open labeled study of 50 @entity1 @entity0 with plasma @entity5  mg/L was conducted. During the 12-week observation phase dietary advice was provided to increase protein intake to 1.2  g/kg/day. In the 12-week treatment phase 45  g of liquid protein supplement was provided at each dialysis treatment. Protein @entity3 appearance (PNA), mid-arm muscle circumference (MAMC), serum albumin, body mass index (BMI) and quality of life (assessed by Short Form-12 questionnaire) were measured at baseline, 12 and 24  weeks. RESULTS: Median plasma @entity4 at baseline was 16.0 (IQR 7.7 to 25.1) mg/L. The mean MAMC was 26.5        3.9  cm, BMI 29.2        6.9  kg/m(2) and plasma albumin 3.8        0.3  g/dl. During the intervention period, mean PNA increased by 0.13  g/kg/d (p   =   0.01) under a mixed effects model. However, there were no clinically or statistically significant effects on MAMC (p   =   0.87), plasma albumin (p   =   0.70), BMI (p   =   0.09), physical (p   =   0.32) or mental (p   =   0.96) composite scores. CONCLUSIONS: In @entity1 @entity0 with elevated plasma @entity4 but otherwise mostly normal nutritional parameters, intra-dialytic oral protein supplement was effective in increasing protein intake but did not provide a detectable impact on nutritional status or quality of life.

title: Supervised oral protein supplementation during dialysis in @entity0 with elevated XXXX levels: a two phase, longitudinal, single center, open labeled study.

answer: @entity4


abstract: BACKGROUND: @entity2 is considered one of the major causes of protein-energy wasting in @entity1 ( @entity1 ) @entity0 . It is unclear whether dietary interventions can impact nutritional status and quality of life in @entity1 @entity0 with elevated @entity4 ( @entity4 ) levels. Therefore, we examined the hypothesis that supervised intra-dialysis protein supplementation in @entity1 @entity0 with elevated plasma @entity4 will improve protein stores and quality of life. METHODS: A 24  week, two phase, longitudinal, single center, open labeled study of 50 @entity1 @entity0 with plasma @entity5  mg/L was conducted. During the 12-week observation phase dietary advice was provided to increase protein intake to 1.2  g/kg/day. In the 12-week treatment phase 45  g of liquid protein supplement was provided at each dialysis treatment. Protein @entity3 appearance (PNA), mid-arm muscle circumference (MAMC), serum albumin, body mass index (BMI) and quality of life (assessed by Short Form-12 questionnaire) were measured at baseline, 12 and 24  weeks. RESULTS: Median plasma @entity4 at baseline was 16.0 (IQR 7.7 to 25.1) mg/L. The mean MAMC was 26.5        3.9  cm, BMI 29.2        6.9  kg/m(2) and plasma albumin 3.8        0.3  g/dl. During the intervention period, mean PNA increased by 0.13  g/kg/d (p   =   0.01) under a mixed effects model. However, there were no clinically or statistically significant effects on MAMC (p   =   0.87), plasma albumin (p   =   0.70), BMI (p   =   0.09), physical (p   =   0.32) or mental (p   =   0.96) composite scores. CONCLUSIONS: In @entity1 @entity0 with elevated plasma @entity4 but otherwise mostly normal nutritional parameters, intra-dialytic oral protein supplement was effective in increasing protein intake but did not provide a detectable impact on nutritional status or quality of life.

title: Supervised oral protein supplementation during dialysis in XXXX with elevated @entity4 levels: a two phase, longitudinal, single center, open labeled study.

answer: @entity0


abstract: Effects of @entity0 and age on @entity4 , @entity2 , @entity3 , @entity6 , @entity5 , and protein were compared in liver, kidney, brain, and muscle of @entity0 (fa/fa) and nonobese (non-fa/fa) male Zucker @entity1 . Blood plasma cerulopasmin, @entity4 , @entity3 , @entity6 , and @entity5 were also determined. Mean brain weight of fa/fa @entity1 was less than that of non-fa/fa @entity1 at 12 weeks of age; mean brain protein concentration was greater in fa/fa than in non-fa/fa at 5 and 12 weeks of age. At 18-19 days of age, mean @entity6 concentration (mg/g protein) in liver of fa/fa was less than that of non-fa/fa. At 5 weeks of age, mean @entity4 concentration (microgram/g protein) in kidney was greater in fa/fa. Mean total @entity4 , @entity2 , @entity3 , @entity6 , and @entity5 in liver and kidney were greater in fa/fa than in non-fa/fa at 5 weeks because of the larger livers and kidneys of fa/fa. Mean concentrations of @entity4 , @entity3 , @entity6 , and @entity5 per gram of brain protein were slightly (6-10%) less in fa/fa than in non-fa/fa at 5 weeks. By 12 weeks, mean concentrations of @entity4 in liver, kidney, (tibialis) muscle, and blood plasma, ceruloplasmin in blood plasma, @entity3 in liver and muscle, @entity2 in muscle, and @entity6 in liver were greater in fa/fa than in non-fa/fa. However, total amount of each mineral in muscle at 12 weeks was less in fa/fa than in non-fa/fa because of the smaller mean muscle weight of fa/fa. Mean concentrations of @entity4 and @entity3 in brain and of @entity2 in liver and brain were less in fa/fa than in non-fa/fa at 12 weeks. The major age-related changes in fa/fa that were not observed in non-fa/fa were large increases in liver and kidney @entity4 between 5 and 12 weeks of age. It seems that the abnormal mineral metabolism is a consequence of the @entity0 , but the mechanisms are not identified.

title: Developmental changes of selected minerals in Zucker XXXX .

answer: @entity1


abstract: PURPOSE: This case report describes the treatment of a rare @entity2 caused by @entity10 with @entity9 and @entity5 . SUMMARY: A 48-year-old @entity0 with significant comorbidities was admitted to our institution with complaints of malaise, @entity6 , and vague persistent @entity1 . He was diagnosed with @entity10 @entity3 and was treated with @entity9 continuous infusion for 10 days without resolution of @entity8 . As surgical intervention was deemed inappropriate, @entity5 was added to the treatment regimen for its antibiofilm activity. After @entity5 initiation, resolution of @entity8 was rapidly achieved. Subsequent blood cultures remained negative, and the @entity0 was discharged home in stable condition to complete six weeks of i.v. @entity9 and @entity5 therapy. The @entity0 continued treatment, as documented by the infusion center, weekly for five weeks. The @entity0 was rehospitalized during his sixth week of treatment due to impending @entity7 , whereupon he was intubated and admitted to the intensive care unit. The @entity0 's cardiac status gradually worsened over the following days, and he ultimately died. Blood cultures from days 1 and 2 of hospitalization revealed no bacterial growth at five days. CONCLUSION: @entity9 and @entity5 therapy in a hospitalized @entity0 with @entity8 and @entity4 caused by @entity10 resulted in rapid eradication of the @entity8 . After more than five weeks of @entity9 - @entity5 treatment, the @entity0 was rehospitalized with worsening cardiac function and died. Blood cultures during the second admission were negative.

title: @entity10 XXXX and @entity3 treated with @entity9 and @entity5 .

answer: @entity8


abstract: PURPOSE: This case report describes the treatment of a rare @entity2 caused by @entity10 with @entity9 and @entity5 . SUMMARY: A 48-year-old @entity0 with significant comorbidities was admitted to our institution with complaints of malaise, @entity6 , and vague persistent @entity1 . He was diagnosed with @entity10 @entity3 and was treated with @entity9 continuous infusion for 10 days without resolution of @entity8 . As surgical intervention was deemed inappropriate, @entity5 was added to the treatment regimen for its antibiofilm activity. After @entity5 initiation, resolution of @entity8 was rapidly achieved. Subsequent blood cultures remained negative, and the @entity0 was discharged home in stable condition to complete six weeks of i.v. @entity9 and @entity5 therapy. The @entity0 continued treatment, as documented by the infusion center, weekly for five weeks. The @entity0 was rehospitalized during his sixth week of treatment due to impending @entity7 , whereupon he was intubated and admitted to the intensive care unit. The @entity0 's cardiac status gradually worsened over the following days, and he ultimately died. Blood cultures from days 1 and 2 of hospitalization revealed no bacterial growth at five days. CONCLUSION: @entity9 and @entity5 therapy in a hospitalized @entity0 with @entity8 and @entity4 caused by @entity10 resulted in rapid eradication of the @entity8 . After more than five weeks of @entity9 - @entity5 treatment, the @entity0 was rehospitalized with worsening cardiac function and died. Blood cultures during the second admission were negative.

title: XXXX @entity8 and @entity3 treated with @entity9 and @entity5 .

answer: @entity10


abstract: PURPOSE: This case report describes the treatment of a rare @entity2 caused by @entity10 with @entity9 and @entity5 . SUMMARY: A 48-year-old @entity0 with significant comorbidities was admitted to our institution with complaints of malaise, @entity6 , and vague persistent @entity1 . He was diagnosed with @entity10 @entity3 and was treated with @entity9 continuous infusion for 10 days without resolution of @entity8 . As surgical intervention was deemed inappropriate, @entity5 was added to the treatment regimen for its antibiofilm activity. After @entity5 initiation, resolution of @entity8 was rapidly achieved. Subsequent blood cultures remained negative, and the @entity0 was discharged home in stable condition to complete six weeks of i.v. @entity9 and @entity5 therapy. The @entity0 continued treatment, as documented by the infusion center, weekly for five weeks. The @entity0 was rehospitalized during his sixth week of treatment due to impending @entity7 , whereupon he was intubated and admitted to the intensive care unit. The @entity0 's cardiac status gradually worsened over the following days, and he ultimately died. Blood cultures from days 1 and 2 of hospitalization revealed no bacterial growth at five days. CONCLUSION: @entity9 and @entity5 therapy in a hospitalized @entity0 with @entity8 and @entity4 caused by @entity10 resulted in rapid eradication of the @entity8 . After more than five weeks of @entity9 - @entity5 treatment, the @entity0 was rehospitalized with worsening cardiac function and died. Blood cultures during the second admission were negative.

title: @entity10 @entity8 and @entity3 treated with XXXX and @entity5 .

answer: @entity9


abstract: PURPOSE: This case report describes the treatment of a rare @entity2 caused by @entity10 with @entity9 and @entity5 . SUMMARY: A 48-year-old @entity0 with significant comorbidities was admitted to our institution with complaints of malaise, @entity6 , and vague persistent @entity1 . He was diagnosed with @entity10 @entity3 and was treated with @entity9 continuous infusion for 10 days without resolution of @entity8 . As surgical intervention was deemed inappropriate, @entity5 was added to the treatment regimen for its antibiofilm activity. After @entity5 initiation, resolution of @entity8 was rapidly achieved. Subsequent blood cultures remained negative, and the @entity0 was discharged home in stable condition to complete six weeks of i.v. @entity9 and @entity5 therapy. The @entity0 continued treatment, as documented by the infusion center, weekly for five weeks. The @entity0 was rehospitalized during his sixth week of treatment due to impending @entity7 , whereupon he was intubated and admitted to the intensive care unit. The @entity0 's cardiac status gradually worsened over the following days, and he ultimately died. Blood cultures from days 1 and 2 of hospitalization revealed no bacterial growth at five days. CONCLUSION: @entity9 and @entity5 therapy in a hospitalized @entity0 with @entity8 and @entity4 caused by @entity10 resulted in rapid eradication of the @entity8 . After more than five weeks of @entity9 - @entity5 treatment, the @entity0 was rehospitalized with worsening cardiac function and died. Blood cultures during the second admission were negative.

title: @entity10 @entity8 and XXXX treated with @entity9 and @entity5 .

answer: @entity3